# PACIFIC-9 (NCT05221840)

> A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05221840
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Durvalumab; Oleclumab; Monalizumab; Placebo
- Enrollment: 1051
- Primary outcome: Progression Free Surival (PFS)

## Commentary we found

- X threads: 21
- Podcasts: 8
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=pacific-9-nct05221840

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05221840", "email": "<work email>"}; the inbox owner confirms by the emailed link.